Back To Top

You have matched to 1 trial

Guest Profile:  No profile selected

Copy link
Sort by zip code: 94107 Hide Map Icon
mail-icon

Register to sign up for Trial Alerts

Receive emails about new trials that match your profile.
1

Rhenium-186 NanoLiposome Radioactive Drug for Leptomeninges Metastases

A Multicenter Phase 1 Study to Determine the Safety and Efficacy of Multiple Doses at Defined Intervals of Rhenium (186Re) Obisbemeda (Rhenium-186 NanoLiposome, 186RNL) Administered Via Intraventricular Catheter for Any Primary Solid Tumor Cancer With Leptomeningeal Metastases (CA2024-LM-001)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of rhenium (186Re) obisbemeda (rhenium-186 nanoliposome), an experimental radioactive drug.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the leptomeninges. You must not have received radiation to the whole brain. Other types of radiation to the brain are allowed. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Rhenium (186Re) obisbemeda (rhenium-186 nanoliposome), by catheter into the brain, multiple times over 13 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The leptomeninges are the inner layers of tissue that line the brain and spinal cord.</li> <li class="seamTextUnorderedListItem">Rhenium (186Re) obisbemeda (rhenium-186 nanoliposome) is an experimental radiopharmaceutical or radioactive drug.</li> <li class="seamTextUnorderedListItem">Radiopharmaceuticals deliver radiation therapy directly and specifically to cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07098806' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://ir.plustherapeutics.com/static-files/415202a9-4f0f-4478-a604-ea0a183c34b7' target='_blank'>Plus Therapeutics: Rhenium (186Re) Obisbemeda (Rhenium-186 Nanoliposome)</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/mbc-radiopharmaceuticals/' target='_blank'>What Are Radiopharmaceuticals and How Are They Used in MBC?</a> </li></ul>
1

Rhenium-186 NanoLiposome Radioactive Drug for Leptomeninges Metastases

A Multicenter Phase 1 Study to Determine the Safety and Efficacy of Multiple Doses at Defined Intervals of Rhenium (186Re) Obisbemeda (Rhenium-186 NanoLiposome, 186RNL) Administered Via Intraventricular Catheter for Any Primary Solid Tumor Cancer With Leptomeningeal Metastases (CA2024-LM-001)
Icon

Nearest Location from 94107:
1481 miles
The Cancer Therapy and Research Center at UTHSCSA
San Antonio, TX

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT07098806

Icon

Phase I

HELP GUIDE